「重要なお知らせ：日本語書籍をご購入いただき、eLibraryをご利用の皆さまへ」
エルゼビアは、より快適にサービスをご利用いただくため、システムの重要なアップデートを実施いたします。
現在eLibraryで日本語電子書籍をご利用のお客様は、今後より高いアクセシビリティとセキュリティを備えた新しいプラットフォーム「eBooks+」へアカウントが2025年11月中旬から下旬に移行されます。
お客様ご自身でのお手続きは不要です。ご利用中のコンテンツはすべて自動的に移行され、移行作業が完了次第、自動的にeBooks+へリダイレクトされます。
(0 rating) 
Book Description
Pulmonary hypertension is defined as a mean pulmonary artery pressure (mPAP) ≥25 mmHg, with Pulmonary Capillary Wedge Pressure ≤ 15 mmHg, measured by cardiac catheterization. The etiology of PH has a varied spectrum extending right from Drugs, toxins and portal hypertension to HIV, Collagen Vascular Diseases and Persistent Pulmonary Hypertension of Newborn, etc.
The estimation of disease prevalence has been nearly impossible owing to the geographic distribution and economic diversity, along with significant regional variations in human development and healthcare infrastructure. A large number of patients with PH never reach the health centers capable of diagnosing the disease condition correctly.
Advance pulmonary vascular disease as a result of uncorrected CHD is a major health challenge in the developing world.
PH exists as a major component of many forms of cardiac and pulmonary disease. While breathlessness is the most common feature of PH, patients often also present with chest pain, syncope, fatigue, weakness and abdominal distension. The precordial signs include a right ventricular lift, accentuated pulmonary component of S2, a pansystolic murmur of Tricuspid regurgitation, a diastolic murmur of pulmonary regurgitation and a right ventricular S3.
The standard diagnostic workup in developed countries includes a series of investigations to rule out the secondary causes. Additional tests are required to estimate the disease severity and plan the appropriate treatment. These include the cardiac catheterization, selective pulmonary angiography by direct injection of pulmonary arteries, high resolution CT scan, cardiac magnetic resonance, ABGs, nocturnal O2 saturation, etc. While most of the basic management is feasible in the Indian conditions, most of the newly introduced drugs are either not available or are available at costs that far exceed the paying capacity of an average citizen of a developing economy. An underdeveloped health insurance system adds further to the financial burden of the treatment.
Measures like formulation of guidelines for diagnosis and treatment of PAH, educating clinicians and scientists and making medications affordable to poor patients might ensue a breakthrough in the overall management of pulmonary hypertension.